Navigation Links
Brigham and Women's Hospital researchers initiate major cardiovascular inflammation reduction trial
Date:8/22/2012

Boston, MA Fifteen years ago, researchers at Brigham and Women's Hospital (BWH) reported that C-reactive protein (CRP), a biomarker of inflammation found in the blood, was as powerful a tool to predict future heart attack and stroke as was total cholesterol. Today, the same research group announces the launch of a new randomized clinical trial, funded by The National Heart, Lung, and Blood Institute (NHLBI), a part of the National Institutes of Health (NIH), to determine whether lowering inflammation with a common anti-inflammatory drug will in turn reduce rates of recurrent heart attack, stroke, and cardiovascular death in high risk patients who have already suffered a prior heart attack.

"We are exceptionally grateful to the National Heart, Lung, and Blood Institute for funding the Cardiovascular Inflammation Reduction Trial" said Paul M Ridker, MD, principal investigator for the new trial and Director of the Center for Cardiovascular Disease Prevention at BWH in Boston. "We believe that the concept of reducing inflammation has enormous potential as a new method to reduce the burden of heart attack and stroke for our patients."

The Cardiovascular Inflammation Reduction Trial (CIRT) will test whether low-dose methotrexate [Trexall (methotrexate tablets USP)], an inexpensive drug widely used to treat rheumatoid arthritis, can reduce the rates of recurrent cardiovascular events among patients with a prior heart attack who also have diabetes or metabolic syndrome, conditions known to be associated with a heightened inflammatory response. Such individuals are at very high risk for second and third cardiac events which are often life-threatening, despite all currently available interventions including aggressive cholesterol reduction with statin therapy.

Researchers will enroll 7,000 patients from up to 400 clinical sites across the United States and Canada. All patients will receive aggressive standard of care and in addition, half will receive low-dose methotrexate (target dose of 20 mg/week) while the other half will receive a placebo. All participants will be followed for 3 to 5 years for recurrent major cardiovascular events.

"Prior research suggests that inflammation plays a critical role in heart attack and stroke," said Gary H. Gibbons, M.D., director of the NHLBI, which is funding the study. "This trial promises to offer evidence about the relative importance of inflammation and may lead to new treatment paradigms for millions of people with cardiovascular disease," added Dr. Gibbons.

"This new study is the end-game for more than fifteen years of research by investigators worldwide demonstrating that inflammation is a central part of the process that leads to heart attack and stroke," Dr. Ridker said. "Whether or not reducing that inflammation can benefit our patients is unknown, but a positive finding in this trial has the potential to dramatically reshape how we think about and treat heart disease."

The concept of treating inflammation to prevent chronic disease has a long history at BWH in Boston. In addition to Dr. Ridker's work, BWH researchers Dr. Peter Libby, chief of the Division of Cardiology, and Dr. Michael Gimbrone, director of Center for Excellence in Vascular Biology, performed ground-breaking work investigating basic mechanisms of inflammation in heart disease. Additionally, low-dose methotrexate as a treatment for rheumatoid arthritis was pioneered at BWH by Dr. Michael Weinblatt and others in the 1980's.

Screening will begin in January 2013 with patient recruitment in March, 2013. Physicians and clinical sites interested in CIRT can obtain further information at www.theCIRT.org.


'/>"/>
Contact: Lori J. Schroth
ljschroth@partners.org
617-534-1604
Brigham and Women's Hospital
Source:Eurekalert

Related medicine news :

1. Higher-spending hospitals have fewer deaths for emergency patients
2. Predictors identified for rehospitalization among post-acute stroke patients
3. More Smog Might Mean More Hospitalizations
4. After Hospitalization, Men More Likely to Show Up in ER
5. Choosing the right hospital may save your babys life
6. Heart Attack Survival Varies Widely Among Hospitals, Study Finds
7. In Some Brain Bleeds, Patients Do Better at High-Volume Hospitals
8. Rate of Hospitalizations for Stroke Has Declined in U.S.
9. Hospital readmission rates linked to availability of care, socioeconomics
10. Availability of Beds, Poverty Drive Costly Hospital Readmissions
11. Inhaled Steroids Lead to Big Drop in Asthma Deaths at Texas Hospital: Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2016)... ... April 29, 2016 , ... Dr. ... of best seller "LOVE, MEDICINE and MIRACLES") addresses touchy topics related to Death ... podcasted thereafter . Dr. Bernie Siegel, author of a plethora of essential ...
(Date:4/29/2016)... Southlake, Texas (PRWEB) , ... April 29, 2016 , ... ... and neck pain, is proud to announce one of their physicians has been invited ... Osteopathic Family Physicians (Texas ACOFP) Family Practice Review conference on April 30, 2016. ...
(Date:4/29/2016)... ... ... Melanoma is the deadliest type of skin cancer. Although only about 1 percent of skin ... More than 10,000 people are expected to die of melanoma this year. The risk increases ... of the most commonly diagnosed cancers in young women. A recent breakthrough in genetic studies ...
(Date:4/29/2016)... ... April 29, 2016 , ... Jvion, ... round of funding led by Eastside Partners, with participation from existing investor Martin ... customer base and accelerate its technology and product roadmap. , “Jvion ...
(Date:4/29/2016)... ... ... Nike Softball Camp at the College of Brockport in New York is ... 10-18. All facets of the game will be covered; hitting, fielding, base-running, and team ... the finest softball facilities in the region. The outstanding professional college staff complement and ...
Breaking Medicine News(10 mins):
(Date:4/27/2016)... , le 27 Avril 2016 ... a progressé de +5% sur le trimestre, soutenu ... de consommables  Croissance de +16% des ... Mauna Kea Technologies (Euronext : MKEA, FR0010609263 ; ... confocale laser, annonce aujourd,hui son chiffre d,affaires pour ...
(Date:4/27/2016)... April 27, 2016 Elekta today ... platform will be the focal point of seven scientific ... European Society for Radiotherapy & Oncology, taking place April ... a state-of-the-art radiotherapy system and a high-field MRI scanner ... see the patient,s anatomy in real time. The MR-linac ...
(Date:4/27/2016)... , April 27, 2016   Zillion ... digital health technology platform, which specializes in live ... into scalable digital products, Zillion enables companies to ... empower consumers to take control of their health. ... video conferencing – including one-to-one, group and webcast ...
Breaking Medicine Technology: